177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer
Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.
United States Kim Chi Kaplan Meier Prostate Cancer Clinical Trials Working Group Lantheus Holdings Inc Common Terminology Criteria
Source: onclive.com